A research of SARS-CoV-2 infection severity and measles-mumps-rubella titers has been published in mBio, the open-access journal of the American Society for Microbiology.
Researchers, in the study titled ‘Analysis of Measles-Mumps-Rubella (MMR) Titers of Recovered Covid-19 Patients’, provide further proof to the theory that the measles-mumps-rubella vaccine provides protection against Covid-19.
Scientists said they found that mumps IgG titers are inversely correlated with severity in recovered Covid-19 patients previously vaccinated with MMR II.
The study’s lead author Jeffrey E Gold said, “We found a statistically significant inverse correlation between mumps titer levels and COVID-19 severity in people under age 42 who have had vaccinations.”
According to Gold, “This adds to other associations demonstrating that the MMR vaccine may be protective against Covid-19.”
Why children are less infected
The study also may explain why children have a much lower Covid-19 case rate than adults, as well as a much lower death rate. The majority of children get their first MMR vaccination around 12 to 15 months of age and a second one from 4 to 6 years of age.
Coauthor David J Hurley, PhD, Professor and Molecular Microbiologist, the University of Georgia, said, “this is the first immunological study to evaluate the relationship between the MMR II vaccine and Covid-19.”
He added: “The MMR II vaccine is considered a safe vaccine with very few side effects. If it has the ultimate benefit of preventing infection from Covid-19, preventing the spread of Covid-19, reducing the severity of it, or a combination of any or all of those, it is a very high reward low risk ratio intervention.”
The researchers found a significant inverse correlation (rs = -0.71, P < 0.001) between mumps titers and Covid-19 severity within the group previously vaccinated with the MMR II vaccine by Merck. Mumps titers of 134 to 300 AU/ml (n=8) were only found in those who were functionally immune or asymptomatic.